ZETEZE ezetimibe/atorvastatin 10mg/20mg tablet blister pack

Country: Ավստրալիա

language: անգլերեն

source: Department of Health (Therapeutic Goods Administration)

active_ingredient:

atorvastatin calcium trihydrate, Quantity: 21.7 mg (Equivalent: atorvastatin, Qty 20 mg); ezetimibe, Quantity: 10 mg

MAH:

ORGANON PHARMA PTY LTD

INN:

atorvastatin calcium trihydrate,Ezetimibe

pharmaceutical_form:

Tablet, multilayer

composition:

Excipient Ingredients: polysorbate 80; magnesium stearate; povidone; lactose monohydrate; sodium lauryl sulfate; croscarmellose sodium; microcrystalline cellulose; calcium carbonate; hyprolose; silicon dioxide; titanium dioxide; macrogol 8000; hypromellose; purified talc

administration_route:

Oral

units_in_package:

10, 30

prescription_type:

(S4) Prescription Only Medicine

therapeutic_indication:

Prevention of Cardiovascular Disease ZETEZE is indicated in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS) taking their maximum tolerated dose of atorvastatin and in need of additional lowering of LDL-C in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy (see Clinical Trials). Primary Hypercholesterolaemia ZETEZE is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia where use of a combination product is appropriate in those patients: - not appropriately controlled with atorvastatin or ezetimibe alone; - or already treated with atorvastatin and ezetimibe Homozygous Familial Hypercholesterolaemia (HoFH) ZETEZE is indicated in patients with HoFH. Patients may also receive adjunctive treatments (e.g. LDL apheresis).

leaflet_short:

Visual Identification: Capsule shaped, biconvex, white to off white tablets, with "333" debossed on one side of the tablet; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 24 Months; Container Temperature: Store below 30 degrees Celsius

authorization_status:

Licence status A

authorization_date:

2015-02-04